Brii Biosciences Ltd. is a biotechnology company dedicated to developing innovative therapies that target significant infectious diseases and central nervous system conditions. Established in 2017 and... Brii Biosciences Ltd. is a biotechnology company dedicated to developing innovative therapies that target significant infectious diseases and central nervous system conditions. Established in 2017 and headquartered in Beijing, China, the company is recognized for its broad pipeline of proprietary drug candidates, particularly addressing major health burdens such as hepatitis B virus (HBV), human immunodeficiency virus (HIV), and multi-drug resistant bacterial infections. Notable products in its HBV portfolio include a therapeutic vaccine and advanced therapeutic agents like siRNA-based and antibody treatments. Brii Biosciences also invests in research for therapies addressing drug-resistant infections and central nervous system disorders. Its primary operations and market focus are in China, where it seeks to mitigate public health challenges through scientific innovation and strategic partnerships. The company’s emphasis on unmet medical needs underscores its role as a key contributor in the biotechnology and medical research sectors.Show lessShow more

Disclosures ESG Data Financial Data

GHG Emissions Climate Targets EU Taxonomy Energy Waste Management

Data not available

Brii Biosciences is not subject to EU Taxonomy reporting

Based on current regulatory requirements, Brii Biosciences is not required to report EU Taxonomy data under the CSRD framework. As a result, we have not conducted a detailed EU Taxonomy data review for this company.

If you believe this assessment should be revisited, you may submit a data coverage request and our team will review the company's regulatory applicability.

Would you like us to review Brii Biosciences's data?

Start your 30-day free trial to request a data review for Brii Biosciences.

Start Free Trial

Legal Center Contact Us